A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism.
about
Evaluation of the pharmacokinetic interaction between lesogaberan (AZD3355) and esomeprazole in healthy subjects.Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mgCYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteersCurrent pharmacotherapy options for gastritis.A benefit-risk assessment of the use of proton pump inhibitors in the elderly.Randomised clinical trial: esomeprazole for the prevention of nonsteroidal anti-inflammatory drug-related peptic ulcers in Japanese patients.Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options.Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors.Pharmacogenomic testing: the case for CYP2C19 proton pump inhibitor gene-drug pairs.In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substratesEsomeprazole for the treatment of peptic ulcer bleeding.Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects.Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine.
P2860
Q33448993-56883F64-83B9-4990-9398-34281D6ABCB8Q35304679-DEE54E4D-0EBD-43A0-83DF-40633724D878Q36164941-CAB4BD9B-BE51-4231-BC9A-307F465A643DQ38061147-38F3298B-7CAF-4228-8D83-F28E5A25A79DQ38196383-2DD1CBF0-B28C-4003-B9BE-2BC5F087F239Q38471578-296D39AD-6A46-4137-ADDE-45C073A47411Q39013343-6F866AAB-7845-423B-BF3C-56DFBEB6602BQ40389903-3F40FD05-775B-4DA4-8909-2E29A11916ECQ41706384-26CC448C-590E-4805-AFBA-105EB75B8104Q41986948-750AD549-52E2-4C37-97A1-D17D3208A385Q42792216-1609F69E-7381-4B4B-8640-5373E026110EQ47404372-5DA84DF7-024F-44F4-B91D-A556AF34A993Q55280841-28E53F7B-1731-43D6-B897-7F1EE0B31CC2
P2860
A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
A comparison of the acid-inhib ...... tics and CYP2C19 polymorphism.
@en
A comparison of the acid-inhib ...... tics and CYP2C19 polymorphism.
@nl
type
label
A comparison of the acid-inhib ...... tics and CYP2C19 polymorphism.
@en
A comparison of the acid-inhib ...... tics and CYP2C19 polymorphism.
@nl
prefLabel
A comparison of the acid-inhib ...... tics and CYP2C19 polymorphism.
@en
A comparison of the acid-inhib ...... tics and CYP2C19 polymorphism.
@nl
P2093
P1476
A comparison of the acid-inhib ...... tics and CYP2C19 polymorphism.
@en
P2093
E J Kuipers
J C Kooiman
N G Hunfeld
P G H Mulder
R A Mathot
R H VAN Schaik
P2860
P304
P356
10.1111/J.1365-2036.2009.04150.X
P407
P577
2010-01-01T00:00:00Z